Dr. Gordillo was born in Badajoz, Spain. She earned her B.S. and Ph.D. degrees in Chemistry from the University of Extremadura (Spain) in 1997 and 2002, respectively. Her research is focused on mass spectrometry analysis of metabolites in biological samples and its implication in diseases.
Dr. Gordillo is currently the Director of UTSW Metabolic Phenotyping Core. The Core provides comprehensive, state-of-the-art measurements of multiple parameters, including: mass spectrometry, physiology, lipid, glucose, and metabokine assays to investigators at UTSWMC. In this way the scientific community has available a centralized service that is more cost effective preventing the duplication of reagents and instrumentation providing consistency in various assays across laboratories. The services are offered to investigators inside and outside UTSW campus
She has several years of industry expertise in the area of mass spectrometry analysis of endogenous and drug metabolites in biological samples. From February 2008 to March 2011, she worked as a Research Scientist at Myrexis Inc. (formerly known as Myriad Pharmaceuticals Inc.) in the Discovery Biology department. Her work involved the development of LC-MS/MS analytical methods to be applied to in vitro and in vivo pharmacodynamics studies, pharmacokinetics of drug candidates in cultured cells, and metabolomics studies. These studies were an important contribution towards the development of MPC-9528, a potent cancer metabolism inhibitor. As a postdoctoral fellow at Oregon State University, she acquired a broad experience in the analysis of metabolites using liquid chromatography separation technologies coupled to triple quadrupole mass spectrometers. She was postdoctoral fellow at UCLA Department of Chemistry and Biochemistry from 2002-2005 where she work under the mentorship of Dr. Kendall N. Houk. Her work focussed on the computational study of the organocatalysis of enantioselective cycloaddition reactions.